Cargando…
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required an alternative method of administration that d...
Autores principales: | Yildiz Pekoz, Ayca, Akbal Dagistan, Ozlem, Fael, Hanan, Culha, Meltem, Erturk, Aybige, Basarir, Nur Sena, Sahin, Gokben, Serhatli, Muge, Cakirca, Gamze, Tekin, Saban, Sen, Leyla Semiha, Sevim, Mustafa, Mulazimoglu Durmusoglu, Lutfiye, Yegen, Berrak C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448368/ https://www.ncbi.nlm.nih.gov/pubmed/36062490 http://dx.doi.org/10.1080/10717544.2022.2118398 |
Ejemplares similares
-
Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects
por: Akbal-Dagistan, Ozlem, et al.
Publicado: (2022) -
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
por: Sahin, Gokben, et al.
Publicado: (2022) -
Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
por: Erelel, Mustafa, et al.
Publicado: (2021) -
A Novel Semi-Solid Self-Emulsifying Formulation of Aprepitant for Oral Delivery: An In Vitro Evaluation
por: Nazlı, Hakan, et al.
Publicado: (2023) -
A new scoring system for early diagnosis of ventilator-associated pneumonia: LUPPIS
por: Haliloglu, Murat, et al.
Publicado: (2020)